Chen et al. reported that a novel oxidative phosphorylation inhibitor (IACS-010759) might be beneficial for PD-1-resistant NSCLC and increase anti-tumor immunity [20]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.